Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sol-Gel Technologies's revenue per share for the
three
months ended in Mar. 2026 was $0.04.
Sol-Gel Technologies's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.63.
Warning Sign:
Sol-Gel Technologies Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Sol-Gel Technologies was 52.60% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 60.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -4.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Sol-Gel Technologies's Revenue per Share or its related term are showing as below:
SLGL'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -47.7 Med: 14.2 Max: 469.1
Current: 60.6
During the past 11 years, Sol-Gel Technologies's highest 3-Year average Revenue Per Share Growth Rate was 469.10% per year. The lowest was -47.70% per year. And the median was 14.20% per year.
SLGL's 3-Year Revenue Growth Rate is ranked better than 85.94% of 768
companies
in the Biotechnology industry
Industry Median: 2.95
vs SLGL: 60.60
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Sol-Gel Technologies Revenue per Share Related Terms
Sol-Gel Technologies Revenue per Share Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLGL vs SABS, BCYC, CYDY: Revenue per Share Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's PS Ratio falls into.
Sol-Gel Technologies Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Sol-Gel Technologies's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sol-Gel Technologies (SLGL) has a Revenue per Share of $6.63 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Sol-Gel Technologies and its competitors. According to the industry distribution chart, Sol-Gel Technologies ranks #108 out of 768 companies in the Biotechnology industry, placing it in the top 14.1%.
Is Sol-Gel Technologies' Revenue per Share too high?
Sol-Gel Technologies' current Revenue per Share is $6.63. The Biotechnology industry median Revenue per Share is 2.95. Sol-Gel Technologies' value of $6.63 is 124.7% above this industry median. Based on the distribution chart, Sol-Gel Technologies ranks #108 out of 768 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sol-Gel Technologies has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Revenue per Share compare to SABS and BCYC?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #108 out of 768 companies for Revenue per Share. This places Sol-Gel Technologies in the top 14% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 2.95. Sol-Gel Technologies' value of $6.63 is 124.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 2.95, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sol-Gel Technologies's current Revenue per Share of $6.63 is 124.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Sol-Gel Technologies and its competitors. For the Biotechnology industry, the median Revenue per Share is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current Revenue per Share is $6.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $67.14, compared to a current price of $80.03 — trading 19.2% above its estimated fair value. The current Revenue per Share is $6.63 and 124.7% above the Biotechnology industry median of 2.95. Sol-Gel Technologies' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Revenue per Share is $6.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $80.03 is trading 19.2% above its estimated GF Value™ of $67.14.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for SLGL:
Revenue per Share: $6.63
GF Value™: $67.14 vs. price of $80.03 (19.2% above fair value)
Industry Position: 124.7% above the Biotechnology median (#108 of 768)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
55GF Score
Get the complete analysis for SLGL
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
